Related Experiment Video
Updated: Jun 24, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Optimizing recent advances in metastatic renal cell carcinoma
Kevin D Courtney1, Toni K Choueiri
1Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
Abstract:
The past few years have seen dramatic advances in the treatment of metastatic renal cell carcinoma (RCC). Dissection of the molecular pathways that regulate proliferation, apoptosis, and angiogenesis has led to the development of targeted therapies such as the receptor tyrosine kinase inhibitors sunitinib and sorafenib, the anti-vascular endothelial growth factor antibody bevacizumab, and a class of rapamycin analogues including everolimus and temsirolimus. Each of these agents has demonstrated clinical efficacy in patients with metastatic RCC. The challenge before us is to expand on these successes by identifying which patients will best respond to these targeted therapies, optimizing the proper combination or sequence of available therapies, developing agents with improved side effect profiles, and identifying novel therapeutic targets to expand our armamentarium in the treatment of RCC.
Insights
Recent advances in metastatic renal cell carcinoma (RCC) treatment include targeted therapies like tyrosine kinase inhibitors and anti-angiogenesis agents. Future efforts focus on personalized treatment, novel combinations, and new therapeutic targets for improved outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (RCC) treatment has advanced significantly.
- Molecular pathway dissection has yielded targeted therapies.
Purpose of the Study:
- To review recent advances in metastatic RCC treatment.
- To outline future challenges and directions in therapy development.
Main Methods:
- Review of targeted therapies including receptor tyrosine kinase inhibitors (sunitinib, sorafenib), anti-VEGF antibody (bevacizumab), and rapamycin analogues (everolimus, temsirolimus).
- Discussion of clinical efficacy of these agents in metastatic RCC.
Main Results:
- Several targeted agents demonstrate clinical efficacy in metastatic RCC.
- Current therapies include sunitinib, sorafenib, bevacizumab, everolimus, and temsirolimus.
Conclusions:
- Future research should focus on patient selection for targeted therapies.
- Optimizing therapy combinations, sequences, and developing novel agents are crucial.
- Identifying new therapeutic targets is essential for expanding RCC treatment options.
